Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis.

Arthritis Res Ther · 2015 · PMC4487200 · PMID 26071192

Europe PMC DOI

hedged sentence

0.0625

closest p · 1.3× alpha

0.0625

boldest claim

The sentences

showed a trendp = 0.0625so close (0.05 < p ≤ 0.1)

Subjects receiving abatacept showed a trend toward improvement in mRSS at week 24 (−8.6 ± 7.5, p = 0.0625) while those in the placebo group did not (−2.3 ± 15, p = 0.75).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.